SG10201403400UA - Sclerostin binding agents - Google Patents

Sclerostin binding agents

Info

Publication number
SG10201403400UA
SG10201403400UA SG10201403400UA SG10201403400UA SG10201403400UA SG 10201403400U A SG10201403400U A SG 10201403400UA SG 10201403400U A SG10201403400U A SG 10201403400UA SG 10201403400U A SG10201403400U A SG 10201403400UA SG 10201403400U A SG10201403400U A SG 10201403400UA
Authority
SG
Singapore
Prior art keywords
binding agents
sclerostin binding
sclerostin
agents
binding
Prior art date
Application number
SG10201403400UA
Other languages
English (en)
Inventor
Paszty Christopher
Kim Robinson Martyn
Graham Kevin
James Henry Alistair
Sue Hoffman Kelly
Latham John
Lawson Alastair
Hsieng Sen Lu
Popplewell Andy
Wenyan Shen
Winkler David
George Winters Aaron
Original Assignee
Ucb Pharma Sa
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201403400U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa, Amgen Inc filed Critical Ucb Pharma Sa
Publication of SG10201403400UA publication Critical patent/SG10201403400UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
SG10201403400UA 2005-05-03 2006-04-28 Sclerostin binding agents SG10201403400UA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67758305P 2005-05-03 2005-05-03
US77684706P 2006-02-24 2006-02-24
US78224406P 2006-03-13 2006-03-13
US79264506P 2006-04-17 2006-04-17
US11/411,003 US7592429B2 (en) 2005-05-03 2006-04-25 Sclerostin-binding antibody

Publications (1)

Publication Number Publication Date
SG10201403400UA true SG10201403400UA (en) 2014-10-30

Family

ID=36992590

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201403400UA SG10201403400UA (en) 2005-05-03 2006-04-28 Sclerostin binding agents

Country Status (42)

Country Link
US (7) US7592429B2 (fr)
EP (7) EP2264063B1 (fr)
JP (4) JP5462484B2 (fr)
KR (4) KR101624809B1 (fr)
CN (4) CN107446043A (fr)
AR (1) AR053266A1 (fr)
AU (2) AU2006242431B2 (fr)
BR (2) BRPI0610197B8 (fr)
CA (2) CA2607197C (fr)
CR (1) CR9524A (fr)
CY (4) CY1114350T1 (fr)
DK (3) DK1891101T3 (fr)
EA (2) EA037044B1 (fr)
ES (4) ES2412857T3 (fr)
GE (2) GEP20125594B (fr)
GT (1) GT200600186A (fr)
HK (3) HK1151803A1 (fr)
HR (3) HRP20211904T1 (fr)
HU (3) HUE057097T2 (fr)
IL (3) IL187106A (fr)
LT (2) LT3670528T (fr)
LU (1) LUC00151I2 (fr)
MA (1) MA29528B1 (fr)
ME (2) ME02085B (fr)
MX (3) MX358705B (fr)
MY (1) MY163480A (fr)
NL (1) NL301034I2 (fr)
NO (4) NO346914B1 (fr)
NZ (2) NZ563539A (fr)
PE (1) PE20070317A1 (fr)
PH (1) PH12015501848A1 (fr)
PL (3) PL3670528T3 (fr)
PT (3) PT1891101E (fr)
RS (3) RS52919B (fr)
SG (1) SG10201403400UA (fr)
SI (3) SI2325199T1 (fr)
TN (1) TNSN07406A1 (fr)
TW (5) TWI778444B (fr)
UA (1) UA123695C2 (fr)
UY (2) UY38207A (fr)
WO (1) WO2006119107A2 (fr)
ZA (1) ZA200709480B (fr)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568033A (en) * 1998-11-27 2011-04-29 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2003087763A2 (fr) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association de polymorphismes dans la region du gene sost avec la densite minerale de l'os
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003276430A1 (en) * 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
NO345763B1 (no) 2003-06-16 2021-07-19 Celltech R&D Inc Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
ITTO20050905A1 (it) * 2005-12-23 2007-06-24 Univ Degli Studi Torino Leganti sintetici capaci di legare l'ocratossina e relativi usi
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
WO2008061013A2 (fr) * 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
EP2144613B1 (fr) 2006-12-29 2018-03-21 OstéoQC Inc. Procédés de modification de croissance osseuse par administration d'antagoniste ou d'agoniste sost ou wise
US7744874B2 (en) 2007-03-20 2010-06-29 Eli Lilly And Company Anti-sclerostin antibodies
US7977313B2 (en) * 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
US20130195881A1 (en) * 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
EP2197421A1 (fr) * 2007-08-31 2010-06-23 Amgen, Inc Formulation protéique à l'état solide
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP3381445B1 (fr) 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
EP2227256A1 (fr) 2007-12-14 2010-09-15 Amgen Inc. Procédé de traitement d'une fracture osseuse à l'aide d'anticorps anti-sclérostine
CN102056946A (zh) 2008-04-11 2011-05-11 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
JP5723769B2 (ja) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
SG2014014708A (en) 2009-02-17 2014-05-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
US20110008766A1 (en) * 2009-05-01 2011-01-13 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
JP2013507928A (ja) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
EP2490957B1 (fr) 2009-10-23 2016-11-23 Amgen, Inc Adaptateur de fiole et système
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9226983B2 (en) 2010-04-07 2016-01-05 Abbvie Inc. TNF-α binding proteins
BR112012026098A2 (pt) 2010-04-16 2016-11-22 Novartis Ag métodos e composições para melhorar a osseointegração de implante.
AU2011250920B2 (en) 2010-05-14 2015-05-21 Amgen Inc. High concentration antibody formulations
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
US9403882B2 (en) * 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US9493541B2 (en) 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
PL2575935T5 (pl) 2010-06-07 2023-12-11 Amgen Inc. Urządzenie do podawania leku
US9617323B2 (en) * 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2815181C (fr) 2010-10-27 2020-09-15 William Gleason Richards Anticorps anti-dkk1 et leurs procedes d'utilisation
CA2816803A1 (fr) * 2010-11-02 2012-05-10 Abbott Laboratories Immunoglobulines a double domaine variable et utilisations de celles-ci
SG189138A1 (en) 2010-11-05 2013-05-31 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2654790B1 (fr) * 2010-12-22 2019-02-06 Teva Pharmaceuticals Australia Pty Ltd Anticorps modifié présentant une demi-vie améliorée
AU2012223358A1 (en) * 2011-03-01 2013-09-05 Amgen Inc. Sclerostin and DKK-1 bispecific binding agents
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
EP2691065B1 (fr) 2011-03-31 2017-03-01 Amgen Inc. Adaptateur de flacon et système
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
CA3145238A1 (fr) 2011-04-20 2012-10-26 Amgen Inc. Appareil auto-injecteur
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
US20140056912A1 (en) 2011-04-29 2014-02-27 Novartis Ag Methods of treating squamous cell carcinoma
CA2842432C (fr) * 2011-08-04 2022-10-04 Amgen Inc. Procede de traitement de defauts d'espace osseux
SI3335747T1 (sl) 2011-10-14 2021-08-31 Amgen Inc. Injektor in postopek sestave
WO2013063114A1 (fr) 2011-10-24 2013-05-02 Abbvie Inc. Agents de liaison immunologique dirigés contre le tnf
SG11201401796SA (en) 2011-10-24 2014-10-30 Abbvie Inc Bispecific immunobinders directed against tnf and il-17
CA2853258A1 (fr) 2011-10-24 2013-05-02 Abbvie Inc. Agents de liaison immunologique diriges contre la sclerostine
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
BR112014016108A2 (pt) 2011-12-28 2018-09-11 Amgen Inc método de tratamento de perda óssea alvelar
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
EA036225B1 (ru) 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
BR112015009961B1 (pt) 2012-11-01 2020-10-20 Abbvie Inc. proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
WO2014118705A1 (fr) 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
EP3593839A1 (fr) 2013-03-15 2020-01-15 Amgen Inc. Cassette de médicaments
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
ES2687282T3 (es) 2013-03-18 2018-10-24 Biocerox Products B.V. Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CN105229028B (zh) * 2013-03-20 2019-11-08 建新公司 用于治疗成骨不全的方法
CN113559363B (zh) 2013-03-22 2023-10-31 美国安进公司 注射器及装配方法
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
WO2015035215A1 (fr) 2013-09-05 2015-03-12 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
KR102458637B1 (ko) 2013-10-24 2022-10-24 암겐 인코포레이티드 주입기 및 조립 방법
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CN104892753B (zh) * 2014-03-07 2019-11-29 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
CA2944767C (fr) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotypage d'immunoglobulines par masse moleculaire precise
MX2016014561A (es) 2014-05-07 2017-06-21 Amgen Inc Autoinyetor con elementos reductores del shock.
CA2949237C (fr) 2014-05-16 2022-08-23 Amgen Inc. Dosage pour la detection de populations de cellules th1 et th2
EP4036924A1 (fr) 2014-06-03 2022-08-03 Amgen, Inc Dispositifs et procédés destinés à aider un utilisateur d'un dispositif d'administration de médicaments
EP3943135A3 (fr) 2014-10-14 2022-06-29 Amgen Inc. Dispositif d'injection de médicament avec indicateurs visuels et audibles
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
JP2017538512A (ja) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
EP3233163B1 (fr) 2014-12-19 2021-10-13 Amgen Inc. Dispositif d'administration de médicament avec détecteur de proximité
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (fr) 2015-02-27 2021-12-15 Amgen Inc. Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
RU2716101C2 (ru) * 2015-03-13 2020-03-05 Цзянсу Хэнжуй Медсин Ко., Лтд. Антитело к склеростину, его антигенсвязывающий фрагмент и медицинское применение
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017039786A1 (fr) 2015-09-02 2017-03-09 Amgen Inc. Adaptateur d'ensemble de seringue pour une seringue
EP3386573B1 (fr) 2015-12-09 2019-10-02 Amgen Inc. Auto-injecteur avec capuchon de signalisation
WO2017120178A1 (fr) 2016-01-06 2017-07-13 Amgen Inc. Auto-injecteur pourvu d'une électronique de signalisation
KR20180133399A (ko) 2016-03-01 2018-12-14 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
LT3219727T (lt) * 2016-03-17 2021-02-10 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (fr) 2016-05-13 2017-11-16 Amgen Inc. Ensemble manchon de flacon
EP3458988B1 (fr) 2016-05-16 2023-10-18 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (fr) 2016-07-01 2019-05-08 Amgen Inc. Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
JP6918808B2 (ja) * 2016-08-31 2021-08-11 栄研化学株式会社 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬
EP3532127A1 (fr) 2016-10-25 2019-09-04 Amgen Inc. Injecteur porté sur le corps
JP7136468B2 (ja) 2016-11-08 2022-09-13 ユニバーシティ オブ マイアミ 抗セクレトグラニンｉｉｉ（ｓｃｇ３）抗体およびその使用
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CA3047221A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclerostine dans le traitement de l'osteogenese imparfaite
WO2018136398A1 (fr) 2017-01-17 2018-07-26 Amgen Inc. Dispositifs d'injection et procédés d'utilisation et d'assemblage associés
WO2018139623A1 (fr) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-sclérostine et procédés d'utilisation
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
EP3582829A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Mécanisme d'insertion pour dispositif d'administration de médicament
WO2018165143A1 (fr) 2017-03-06 2018-09-13 Amgen Inc. Dispositif d'administration de médicaments doté d'une fonction de prévention d'activation
MX2019010543A (es) 2017-03-07 2019-10-21 Amgen Inc Insercion de agujas por sobrepresion.
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
BR112019020053B1 (pt) 2017-03-28 2023-10-10 Amgen Inc Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
US20220135670A1 (en) * 2017-04-27 2022-05-05 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
WO2018201064A1 (fr) 2017-04-28 2018-11-01 Amgen Inc. Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
EP3641857A1 (fr) 2017-06-22 2020-04-29 Amgen Inc. Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (fr) 2017-06-23 2018-12-27 Amgen Inc. Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
EP3651832B1 (fr) 2017-07-14 2023-12-13 Amgen Inc. Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
WO2019018169A1 (fr) 2017-07-21 2019-01-24 Amgen Inc. Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
UA127219C2 (uk) 2017-07-27 2023-06-14 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, що містить анти-sost антитіло, та її застосування
BR112020001922A2 (pt) 2017-08-01 2020-08-04 Amgen Inc. sistemas e métodos para realização de um ensaio de glicanas em tempo real de uma amostra
EA202090399A1 (ru) 2017-08-01 2020-05-20 Эмджен Инк. Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (fr) 2017-08-18 2019-02-21 Amgen Inc. Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019051047A1 (fr) 2017-09-07 2019-03-14 University Of Florida Research Foundation, Inc. Lymphocytes t de récepteurs d'antigènes chimériques exprimant le récepteur de l'interleukine-8
EP3681528A4 (fr) 2017-09-13 2021-07-21 Mayo Foundation for Medical Education and Research Identification et surveillance d'un inhibiteur d'apoptose de macrophage
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
WO2019070552A1 (fr) 2017-10-06 2019-04-11 Amgen Inc. Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703779A1 (fr) 2017-11-03 2020-09-09 Amgen Inc. Systèmes et approches pour stériliser un dispositif d'administration de médicament
WO2019090303A1 (fr) 2017-11-06 2019-05-09 Amgen Inc. Ensembles de remplissage-finition et procédés associés
EP3706830A1 (fr) 2017-11-06 2020-09-16 Amgen Inc. Dispositif d'administration de médicament avec détection de positionnement et de débit
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
WO2019178151A1 (fr) 2018-03-13 2019-09-19 Amgen Inc. Procédés de préparation de polypeptides résistant à la trypsine pour analyse par spectrométrie de masse
EP3765857A1 (fr) 2018-03-13 2021-01-20 Amgen Inc. Digestion séquentielle de polypeptides pour une analyse par spectrométrie de masse
AU2019243848A1 (en) 2018-03-26 2020-09-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
MA52217A (fr) * 2018-03-30 2021-02-17 Amgen Inc Variants d'anticorps anti-c-terminal
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
CA3104386A1 (fr) 2018-07-02 2020-01-09 Amgen Inc. Proteine de liaison a l'antigene anti-steap1
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020023336A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs hybrides d'administration de médicament dotés d'une partie de préhension
WO2020023444A1 (fr) 2018-07-24 2020-01-30 Amgen Inc. Dispositifs d'administration pour l'administration de médicaments
US20210228797A1 (en) 2018-07-31 2021-07-29 Amgen Inc. Fluid path assembly for a drug delivery device
KR20210043607A (ko) 2018-08-10 2021-04-21 암젠 인크 항체 제약 제형의 제조 방법
WO2020068623A1 (fr) 2018-09-24 2020-04-02 Amgen Inc. Systèmes et procédés de dosage interventionnel
EP3856283A1 (fr) 2018-09-28 2021-08-04 Amgen Inc. Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
CA3110529A1 (fr) 2018-10-02 2020-04-09 Amgen Inc. Systemes d'injection pour administration de medicament avec transmission de force interne
EP3860686A1 (fr) 2018-10-05 2021-08-11 Amgen Inc. Dispositif d'administration de médicament ayant un indicateur de dose
WO2020081480A1 (fr) 2018-10-15 2020-04-23 Amgen Inc. Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
JP2022504769A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
US20220146413A1 (en) 2018-12-14 2022-05-12 Amgen Inc. System suitability method for use with protein concentration determination by slope
EP3924083B1 (fr) 2019-02-14 2024-05-15 Amgen Inc. Systèmes et procédés de préparation d'un échantillon et de réalisation d'un dosage en temps réel de l'échantillon
WO2020172293A1 (fr) 2019-02-20 2020-08-27 Amgen Inc. Procédés de détermination de la stabilité de protéines
JP2022522816A (ja) 2019-03-04 2022-04-20 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
CN109897105B (zh) * 2019-03-22 2022-05-20 天承南运(天津)科技有限公司 Ev71病毒的单克隆抗体、其制备方法及其检测试纸条
AU2020245573A1 (en) 2019-03-27 2021-09-30 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
MX2022001805A (es) 2019-08-12 2022-06-08 Amgen Inc Formulaciones de anticuerpos anti-esclerostina.
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
JP2022549329A (ja) 2019-09-26 2022-11-24 アムジェン インコーポレイテッド 抗体組成物を製造する方法
US20230183371A1 (en) * 2020-04-30 2023-06-15 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
CN111537737B (zh) * 2020-05-18 2023-05-12 巴迪泰（广西）生物科技有限公司 降钙素原与c-反应蛋白联合检测试剂盒
WO2021247892A1 (fr) 2020-06-04 2021-12-09 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
JP2023543167A (ja) 2020-09-18 2023-10-13 アムジエン・インコーポレーテツド ペプチドマッピング分析のための試料を処理する方法
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
US20240010672A1 (en) 2020-11-05 2024-01-11 Amgen Inc. Materials and methods for protein processing
KR102255372B1 (ko) 2020-11-24 2021-05-25 (주)발맥스기술 간편 제작 설치 가능 bog 열교환장치
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2022261021A1 (fr) 2021-06-07 2022-12-15 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CA3237662A1 (fr) 2021-11-09 2023-05-19 Amgen Inc. Production de proteines therapeutiques
WO2023179791A1 (fr) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Traitement de troubles musculo-squelettiques
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) 1861-04-09 Coffee-pot
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
JPS5955608A (ja) * 1982-09-24 1984-03-30 Hitachi Ltd 増幅器
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
JPH06502311A (ja) 1990-10-22 1994-03-17 フォックス・チェイス・キャンサー・センター Ｒｎａ療法を提供するためのｄｎａ構造
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JP3370324B2 (ja) * 1991-04-25 2003-01-27 中外製薬株式会社 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
WO1994028929A1 (fr) 1993-06-07 1994-12-22 Genentech, Inc. Polypeptides d'enveloppe du vih
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JPH10511840A (ja) 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド 形態形成タンパク質特異細胞表面レセプターおよびその使用
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (fr) 1995-06-05 1996-12-12 Gregg A. Hastings Facteur de croissance humain du type ccn
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP0912738B1 (fr) 1996-05-22 2008-07-30 Viventia Biotech Inc. Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
CA2293632C (fr) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AU8555798A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ568033A (en) 1998-11-27 2011-04-29 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
EP1151002A4 (fr) * 1999-01-29 2002-05-02 Imclone Systems Inc Anticorps specifiques au kdr et leurs utilisations
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
ATE440109T1 (de) 1999-06-09 2009-09-15 Genentech Inc Methoden zur diagnose von tumoren
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
WO2001064885A1 (fr) 2000-03-02 2001-09-07 Amgen, Inc. Molecules de type chordine 2 et utilisations de celles-ci
JP2003534813A (ja) 2000-06-01 2003-11-25 アムジェン インコーポレーテッド シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用
AU2001272482A1 (en) 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
CA2421056A1 (fr) 2000-09-01 2002-03-28 Genentech, Inc. Polypeptide servant de marqueur diagnostique de presence de tumeurs du colon
EP2116265B1 (fr) 2000-10-12 2020-12-23 Genentech, Inc. Formulations de protéines concentrées à viscosité réduite
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (fr) 2001-03-13 2002-09-13 The Minister Of National Defence Clonage, expression, sequencage et amelioration fonctionnelle de l'anticorps monoclonal a fragment variable et a chaine simple dirige contre le virus de l'encephalomyelite equine du venezuela
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
JP2005512962A (ja) * 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
AUPR837201A0 (en) 2001-10-19 2001-11-15 BUKILIC, Aleksandar Method and apparatus for cleaning and disinfecting a toothbrush
AU2002357107B2 (en) 2001-12-06 2008-01-10 Biocontrol Systems, Inc. Sample collection and testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP4662714B2 (ja) * 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
WO2003087763A2 (fr) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association de polymorphismes dans la region du gene sost avec la densite minerale de l'os
FR2838379B1 (fr) 2002-04-12 2005-06-24 Valeo Climatisation Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7758876B2 (en) 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
DE10255152A1 (de) 2002-11-26 2004-06-03 Von Langen Ursula Lang Schadstoffsauger
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
EP1608399B1 (fr) 2003-03-14 2012-01-11 Ucb Manufacturing, Inc. Complexe entre la sclérostine et la noggine ou la chordine, et agents modulant la formation dudit complexe
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
NO345763B1 (no) 2003-06-16 2021-07-19 Celltech R&D Inc Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
WO2005018912A1 (fr) * 2003-07-21 2005-03-03 Alpla-Werke Alwin Lehner Gmbh & Co. Kg Procede de fabrication d'une preforme pour bouteilles en plastique
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
JP4840939B2 (ja) 2004-08-04 2011-12-21 アムジェン インコーポレイテッド Ｄｋｋ−１に対する抗体
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1981910B1 (fr) 2006-01-13 2013-06-26 A Chan Holding B.V. Méthode d'identification d'un inhibiteur de l'interaction entre le glypican et la sclerostine
WO2008061013A2 (fr) 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2144613B1 (fr) 2006-12-29 2018-03-21 OstéoQC Inc. Procédés de modification de croissance osseuse par administration d'antagoniste ou d'agoniste sost ou wise
KR20090115133A (ko) 2007-02-02 2009-11-04 노파르티스 아게 골-관련 장애를 치료하기 위한 스클레로스틴 결합 파트너의 조절물질
US7744874B2 (en) 2007-03-20 2010-06-29 Eli Lilly And Company Anti-sclerostin antibodies
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
DK2567709T3 (en) 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
EP2227256A1 (fr) 2007-12-14 2010-09-15 Amgen Inc. Procédé de traitement d'une fracture osseuse à l'aide d'anticorps anti-sclérostine
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2010100200A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Préparation d'anticorps lyophilisée
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
AU2011250920B2 (en) * 2010-05-14 2015-05-21 Amgen Inc. High concentration antibody formulations
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
CA2815181C (fr) 2010-10-27 2020-09-15 William Gleason Richards Anticorps anti-dkk1 et leurs procedes d'utilisation
AU2012223358A1 (en) * 2011-03-01 2013-09-05 Amgen Inc. Sclerostin and DKK-1 bispecific binding agents
SG193610A1 (en) * 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
CA2842432C (fr) * 2011-08-04 2022-10-04 Amgen Inc. Procede de traitement de defauts d'espace osseux
BR112014016108A2 (pt) * 2011-12-28 2018-09-11 Amgen Inc método de tratamento de perda óssea alvelar
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA52217A (fr) * 2018-03-30 2021-02-17 Amgen Inc Variants d'anticorps anti-c-terminal

Also Published As

Publication number Publication date
US20160168241A1 (en) 2016-06-16
ZA200709480B (en) 2010-07-28
EA037044B1 (ru) 2021-01-29
ES2537278T3 (es) 2015-06-05
IL224967B (en) 2019-03-31
TW202323271A (zh) 2023-06-16
AU2006242476A1 (en) 2006-11-09
CN103435698B (zh) 2018-08-31
BR122020023315B1 (pt) 2021-06-08
WO2006119107A2 (fr) 2006-11-09
US10562964B2 (en) 2020-02-18
JP5789652B2 (ja) 2015-10-07
PE20070317A1 (es) 2007-04-27
NO2021014I1 (no) 2021-03-24
NZ563539A (en) 2011-04-29
KR101450888B1 (ko) 2014-10-16
RS62685B1 (sr) 2021-12-31
MX2007013759A (es) 2008-04-29
EP1891101B8 (fr) 2013-06-26
PT1891101E (pt) 2013-08-23
RS54049B1 (en) 2015-10-30
CY2020009I2 (el) 2020-11-25
EP3670528B1 (fr) 2021-09-08
US20130203965A1 (en) 2013-08-08
JP2014012001A (ja) 2014-01-23
SI1891101T1 (sl) 2013-10-30
TWI712613B (zh) 2020-12-11
US11939372B2 (en) 2024-03-26
EA201400933A1 (ru) 2015-04-30
TW200716667A (en) 2007-05-01
RS52919B (en) 2014-02-28
LTC1891101I2 (lt) 2020-09-25
HK1108705A1 (en) 2008-05-16
DK1891101T3 (da) 2013-08-26
IL187106A (en) 2015-10-29
US8383801B2 (en) 2013-02-26
EA021539B1 (ru) 2015-07-30
SI3670528T1 (sl) 2022-01-31
BRPI0610197A2 (pt) 2010-06-01
EP2264063A1 (fr) 2010-12-22
PL3670528T3 (pl) 2022-01-31
HUE057097T2 (hu) 2022-04-28
ES2689143T3 (es) 2018-11-08
HUE025530T2 (en) 2016-04-28
NZ591636A (en) 2012-10-26
EP2264063B1 (fr) 2018-06-27
JP5391360B2 (ja) 2014-01-15
HRP20150597T1 (hr) 2015-09-11
NL301034I2 (nl) 2020-05-13
NO345294B1 (no) 2020-11-30
TWI778444B (zh) 2022-09-21
EA200702402A1 (ru) 2008-04-28
LUC00151I1 (fr) 2020-03-16
JP5409952B2 (ja) 2014-02-05
MA29528B1 (fr) 2008-06-02
UY38207A (es) 2020-11-30
PT3670528T (pt) 2021-12-09
HK1151803A1 (en) 2012-02-10
US7872106B2 (en) 2011-01-18
ES2412857T3 (es) 2013-07-12
BRPI0610197B1 (pt) 2021-05-11
TWI494320B (zh) 2015-08-01
CR9524A (es) 2008-05-21
KR20140037293A (ko) 2014-03-26
IL187106A0 (en) 2008-02-09
CA2607197A1 (fr) 2006-11-09
HUS2000007I1 (hu) 2020-03-30
CN107446043A (zh) 2017-12-08
PT2325199E (pt) 2015-07-10
HRP20130803T1 (hr) 2013-11-08
US20090304713A1 (en) 2009-12-10
DK2325199T3 (da) 2015-05-26
EP1891101B1 (fr) 2013-05-22
AR053266A1 (es) 2007-04-25
JP2013249303A (ja) 2013-12-12
US20130121997A1 (en) 2013-05-16
EP2336163A1 (fr) 2011-06-22
NO346914B1 (no) 2023-02-27
LTPA2020506I1 (lt) 2020-04-27
KR20150117302A (ko) 2015-10-19
HRP20211904T1 (hr) 2022-03-04
JP2008539726A (ja) 2008-11-20
ME02085B (fr) 2014-02-28
PH12015501848A1 (en) 2020-07-06
TW201741332A (zh) 2017-12-01
MY163480A (en) 2017-09-15
JP2014061000A (ja) 2014-04-10
DK3670528T3 (da) 2021-12-06
US8637643B2 (en) 2014-01-28
ES2902548T3 (es) 2022-03-28
NO20076046L (no) 2008-01-30
CY2020009I1 (el) 2020-11-25
JP5462484B2 (ja) 2014-04-02
IL224968B (en) 2018-03-29
CN103819558B (zh) 2016-08-24
PL2325199T3 (pl) 2015-08-31
NO20201120A1 (no) 2008-01-30
AU2006242476B2 (en) 2012-05-31
EP3985015A1 (fr) 2022-04-20
MX358705B (es) 2018-08-31
CY1116525T1 (el) 2017-03-15
US20110097342A1 (en) 2011-04-28
US20070110747A1 (en) 2007-05-17
EP1891101A2 (fr) 2008-02-27
BRPI0610197B8 (pt) 2021-05-25
TW202108605A (zh) 2021-03-01
PL1891101T3 (pl) 2013-11-29
CN101287756B (zh) 2014-06-25
UA123695C2 (uk) 2021-05-19
GT200600186A (es) 2007-02-09
EP2325199B1 (fr) 2015-03-04
GEP20166454B (en) 2016-04-11
SI2325199T1 (sl) 2015-07-31
EP2325199A1 (fr) 2011-05-25
TNSN07406A1 (en) 2009-03-17
EP3670528A1 (fr) 2020-06-24
CY1114350T1 (el) 2016-08-31
NO20230084A1 (no) 2008-01-30
KR101653122B1 (ko) 2016-08-31
WO2006119107A3 (fr) 2006-12-28
AU2006242431B2 (en) 2012-11-08
CN101287756A (zh) 2008-10-15
HK1198444A1 (en) 2015-04-24
UY29514A1 (es) 2006-11-30
CA2607197C (fr) 2016-12-13
KR20080011420A (ko) 2008-02-04
US20200048338A1 (en) 2020-02-13
EP2325200A1 (fr) 2011-05-25
AU2006242431A1 (en) 2006-11-09
CN103435698A (zh) 2013-12-11
TW201323438A (zh) 2013-06-16
CY1124802T1 (el) 2022-11-25
LUC00151I2 (fr) 2021-02-15
GEP20125594B (en) 2012-08-10
US9296812B2 (en) 2016-03-29
CN103819558A (zh) 2014-05-28
LT3670528T (lt) 2021-12-27
WO2006119107A9 (fr) 2007-09-20
CA2947080A1 (fr) 2006-11-09
KR20130126752A (ko) 2013-11-20
KR101624809B1 (ko) 2016-05-26
MX2018005512A (es) 2021-11-16
ME02247B (fr) 2015-10-30
US7592429B2 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
HUS2000007I1 (hu) Szklerosztin kötõ szerek
GB0521991D0 (en) Siglec-9 binding agents
SI2251351T2 (sl) Sklerostinski epitopi
IL182279A0 (en) Angiopoietin-2-specific binding agents
GB0404187D0 (en) Binding agents
GB0511590D0 (en) Anti-thrombotic agents
GB0520523D0 (en) Object binding
ZA200900349B (en) Sclerostin binding agents
GB2422543B (en) Louse-killing agents
GB0625144D0 (en) Novel binding agents
GB0511561D0 (en) Anti-Thrombotic agents
GB0520934D0 (en) Object binding